Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic NK Cells + Immunotherapy in Extensive Small Cell Lung Cancer
NCT07759856Phase 2Recruiting
- Sponsor
- Tianjin First Central Hospital
- Start
- Aug 2026
- Primary completion
- Aug 2028
- Countries
- 1
01
Overview
A Phase 2 trial of allogeneic natural killer cells in small cell lung cancer (SCLC), sponsored by Tianjin First Central Hospital. Started Aug 2026; status: recruiting.
02
Drugs
allogeneic natural killer cells
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT07759856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07759856.